Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1978102 | 0.87 | KMT2A (0.38) | ALDH1A1POLBKMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL15315888 | 0.86 | ALDH1A1 (0.36) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL12346101 | 0.85 | ALDH1A1 (0.38) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL13161594 | 0.83 | ALDH1A1 (0.33) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL14212551 | 0.83 | ALDH1A1 (0.41) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL11920271 | 0.81 | ALDH1A1 (0.40) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL16699602 | 0.81 | SMN1; SMN2 (0.39) | ALDH1A1POLBKMT2AMAPK1NPC1 | |
| SCHEMBL12346121 | 0.80 | ALDH1A1 (0.40) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL3376814 | 0.80 | ALDH1A1 (0.40) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL16897503 | 0.80 | ALDH1A1 (0.40) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683912-A1 | SUBSTITUTED THIOPHENE FUSED CYCLOHEXANONE DERIVATIVES, COMPOSITIONS COMPRISING THE SAME AND THEIR USE AS PHARMACEUTICALS | Neurasic Therapeutics Inc. (CA) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025035205-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A SUBSTITUTED THIOPHENE FUSED CYCLOHEXANONE DERIVATIVE AND A CYCLOOXYGENASE (COX) INHIBITOR, AND THEIR USE FOR THE TREATMENT OF PAIN | NEURASIC THERAPEUTICS INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| WO-2024192520-A1 | SUBSTITUTED THIOPHENE FUSED CYCLOHEXANONE DERIVATIVES, COMPOSITIONS COMPRISING THE SAME AND THEIR USE AS PHARMACEUTICALS | NEURASIC THERAPEUTICS INC. (CA) | 2024-09-26 | — | — | WO | disclosed |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| EP-4259605-A1 | 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | Astrazeneca AB (SE) | 2023-10-18 | — | — | EP | disclosed |
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | MERCK SHARP & DOHME LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2012123468-A1 | NEW AZASPIRODECANONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012123468-A1 | NEW AZASPIRODECANONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238613-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238613-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
| EP-2488493-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
| WO-2011045292-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011045292-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238613-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES | SEC61B, SEC61A1, SEC22B | ALDH1A1 3041/4885CYP3A4 71/4885CYP2C19 228/4885 |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | ALDH1A1 1531/4885CYP3A4 3322/4885CYP2C19 3076/4885 |
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | PRMT1, PRMT5, PRMT3 | ALDH1A1 1831/4885CYP3A4 2631/4885CYP2C19 3541/4885 |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LPL, MGLL, LIPE | ALDH1A1 1748/4885CYP3A4 2503/4885CYP2C19 2236/4885 |
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | KEAP1, NFE2L2, NQO1 | ALDH1A1 380/4885CYP3A4 1104/4885CYP2C19 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.